Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment

Leukemia Research

Volumn 27, Issue 5, 2003, Pages 375-380

  Tsimberidou, Apostolia Maria ^a   Waddelow, Tracey ^a   Kantarjian, Hagop M ^a   Albitar, Maher ^a   Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Enbrel; Multiple myeloma; Refractory; TNF

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL DISCOMFORT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERBILIRUBINEMIA; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOGLOBULIN G; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; LYMPHOKINES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PILOT PROJECTS; RECEPTORS, TUMOR NECROSIS FACTOR; SALVAGE THERAPY; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037400526     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00082-6     Document Type: Article

References (41)

1. Giles F.J. Multiple myeloma and other differentiated B-cell disorders. Curr. Opin. Hematol. 1:1994;278-284.
2. Giles F.J. Refractory multiple myeloma: recent advances in therapy. Hematol. Pathol. 9:1995;121-140.
3. Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. New Engl. J. Med. 310:1984;1353-1356.
4. Barlogie B., Desikan R., Eddlemon P.et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood. 98:2001;492-494.
5. Singhal S., Mehta J., Desikan R.et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. New Engl. J. Med. 341:1999;1565-1571.
6. Jourdan M., Tarte K., Legouffe E., Brochier J., Rossi J.F., Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur. Cytokine Network. 10:1999;65-70.
7. Hallek M., Leif Bergsagel P., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 91:1998;3-21.
8. Borset M., Waage A., Brekke O.L., Helseth E. TNF and IL-6 are potent growth factors for OH-2: a novel human myeloma cell line. Eur. J. Haematol. 536:1994;31-37.
9. Borset M., Medvedev A., Sundan A., Espevik T. The role of the two TNF receptors in proliferation, NF-Kappa B activation and discrimination between TNF and LT α signalling in the human myeloma cell line OH-2. Cytokine. 8:1996;430-438.
10. Hata H., Matsuzaki H., Takatsuki K. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor α, in the myeloma cell line KHM-1A. Acta Haematol. 83:1990;133-136.
11. Filella X., Blade J., Guillermo A., Molina R., Rozman C., Ballesta A. Cytokines (IL-6, TNFα, IL-1α) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Ca Detecti. Prevent. 20:1996;52-56.
12. Gowen M., Wood D.D., Ihrie E.J., McGuire M.K., Russell R.G. An interleukin-1 like factor stimulates bone resorption in vitro. Nature. 306:1983;378-380.
13. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 319:1986;516-518.
14. Torcia M., Lucibello M., Edouard V.et al. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp. Hematol. 24:1996;868-874.
15. Bataille R. New insight in the clinical biology of myltiple myeloma. Sem. Hematol. 34:1997;23-28.
16. Gazitt Y., Tian E., Barlogie B.et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood. 87:1996;805-811.
17. Lichtenstein A., Berenson J.R., Norman D., Chang M.P., Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood. 74:1989;1266-1273.
18. Smith C.A., Davis T., Anderson D.et al. A receptor for tumor necosis factor defines an unusual family of cellular and viral proteins. Science. 248:1990;1019-1023.
19. Loetscher H., Pan Y.C., Lahm H.W.et al. Molecular cloning and expression of the human 55 kDa tumor necrosis factor receptor. Cell. 61:1990;351-359.
20. Mohler K.M., Torrance D.S., Smith C.A.et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1993;1548-1561.
21. Moreland L.W., Baumgartner S.W., Schiff M.H.et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. 337:1997;141-147.
22. Moreland L.W., Schiff M.H., Baumgartner S.W.et al. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 130:1999;478-486.
23. Skytta E., Pohjankoski H., Savolainen A.et al. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 18:2000;533-534.
24. Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann. Rheum. Dis. 59:2000;i46-49.
25. Stone J.H., Uhlfelder M.L., Hellmann D.B., Crook S., Bedocs N.M., Hoffman G.S. Etanercept combined with conventional treatment in Wegener's granulomatosis: a 6 months open-label trial to evaluate safety. Arthritis Rheum. 44:2001;1149-1154.
26. Nam MH, Reda D, Boujoukos AJ, Agosti J, Suffredini AF. Recombinant soluble tumor necrosis factor (TNF) receptor (TNFC:Fc): safety and pharmacokinetics in human volunteers. Clin Res 1993;41.
27. Bozkurt B., Torre-Amione G., Warren M.S.et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation. 103:2001;1044-1047.
28. Deswal A., Bozkurt B., Seta Y.et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 99:1999;3224-3226.
29. Fisher C.J.J., Agosti J.M., Opal S.M.et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. New Engl. J. Med. 334:1996;1697-1702.
30. Abraham E., Wunderink R., Silverman H. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA. 273:1995;934-941.
31. Carlet J, Cohen J, Andersson J, et al. INTERSEPT: an international efficacy and safety study of monoclonal antibody to human tumor necrosis factor (hTNF) in patients with the sepsis syndrome. In: Proceedings of the Program and Abstracts of the 34th Interscience Conference on Anti-microbial Agents and Chemotherapy. American Society for Microbiology. Orlando, FL, 1994.
32. Institute NC. Guidelines for reporting of adverse drug reactions. Bethesda (MD): Division of Cancer Treatment, National Cancer Institute, 1998.
33. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting features, response to treatment, and survival. Cancer. 36:1975;842.
34. Alldred A. Etanercept in rheumatoid arthritis. Exp. Opin. Pharmacother. 2:2001;1137-1148.
35. Feldmann M., Maini R.N. Anti-TNFα therapy of rheumatoid arthritis: what we have learned? Ann. Rev. Immunol. 19:2001;163-196.
36. Eason J.D., Pascual M., Wee S.et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation. 61:1996;224-228.
37. Neben K, Mytilineos J, Moehler TM, et al. Genetic polymorphism in the tumor necrosis factor-α locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma, vol. 98. Blood. Orlando: ASH, 2001.
38. Sivaraman S, Deshpande G, Tao M, et al. Effect of in vitro administration of TNF receptor fusion protein (TNFR:Fc) on the biological characteristics of AML cells, vol. 96. Blood. San Francisco (CA): ASH, 2000.
39. Raza A, Dutt D, Lisak L, et al. Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic Syndromes, vol. 96. Blood. Orlando: ASH, 2001.
40. Steensma DP, Mesa RA, Li CY, et al. Etanercept palliates constitutional symptoms in myelofibrosis with myeloid metaplasia: Results of a Pilot Study, vol. 96, Blood. Orlando: ASH. 2001.
41. Tsimberidou AM, Thomas DA, O'Brien S, et al. Recombinant human soluble tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory hematological malignancies, vol. 98. Orlando: ASH, 2001.